netFormulary NHS
Herefordshire & Worcestershire
Medicines and Prescribing Committee
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Erlotinib to top
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds to top
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors
Cytotoxic Drug Afatinib (Giotrif )
View adult BNF View SPC online View childrens BNF
Formulary
Red

For use in line with NICE TA310: 

Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:
the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
the person has not previously had an EGFR-TK inhibitor and
the manufacturer provides afatinib with the discount agreed in the patient access scheme.

Commissioned by NHSE

 
Link  NICE TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
 
Dasatinib (Sprycel)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA425 and NICE TA426

NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.

NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes

Commissioned by NHSE

 
Link  Link to CDF secure application site
Link  NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
 
Erlotinib (Tarceva)
View adult BNF View SPC online View childrens BNF
Formulary
Red

First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer in line with NICE TA258 

Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK POSITIVE (or likely to be) in line with NICE TA374 

Commissioned by NHSE

 
Link  NICE TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
 
Cytotoxic Drug Everolimus (Afinitor)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Treating advanced breast cancer in combination with exemestane after endocrine therapy in line with NICE TA421

Commissioned by NHSE


 
Link  NICE TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
 
Gefitinib (Iressa)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line With NICE TA192 and NICE TA374

Commissioned by NHSE

 
Link  NICE TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
 
Cytotoxic Drug Imatinib (Gilvec)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA86 & NICE TA326:

Adjuvant treatment of gastro-intestinal stromal tumours (GIST), in patients considered at high risk of relapse (based on risk criteria or mutation analysis), for up to 3 years. 

NICE TA209 specifies doses above 400mg not recommended.


NICE TA70 & TA426:
Imatinib is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults.

Commissioned by NHSE

 
Link  NICE TA86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Link  NICE TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA70 Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  Link to CDF secure application site
 
Nilotinib (Tasigna)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA425 and TA426.

NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes
(NHSE is the responsible commissioner)

NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.

Commissioned by NHSE

 
Link  NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
 
Palbociclib (Ibrance)
View adult BNF View SPC online View childrens BNF
Formulary
Red

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA495 

With fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer in line with NICE TA619 

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
 
Regorafenib (Stivarga)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For previously treated unresectable or metastatic gastrointestinal stromal tumours in line with NICE TA488 

For previously treated advanced hepatocellular carcinoma in line with NICE TA555 

 
Link  Link to CDF secure application site
Link   NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
 
Ribociclib (Kisqali)
View adult BNF View SPC online View childrens BNF
Formulary
Red

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA496.

Commissioned by NHSE

 
Link   NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
 
Sorafenib (Nexavar)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Commissioned by NHSE

 
Link  Link to CDF secure application site
 
Sunitinib (Sutent)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Advanced and/or metastatic renal cell carcinoma in line with NICE TA169 

Gastrointestinal stromal tumours in line with NICE TA179 .

Commissioned by NHSE 

 
Link  Link to CDF secure application site
Link   NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA169: Renal cell carcinoma - sunitinib
 
Cytotoxic Drug Temsirolimus (Torisel)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
 
Link  Link to CDF secure application site
 
Tivozanib (Fotivda)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For treating advanced renal cell carcinoma, in line with NICE TA512

 
Link  Link to CDF secure application site
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
 
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisimerase I inhibitors to top
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab
08.01.05  Expand sub section  Tretinoin
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Secondary care only, not to be prescribed in primary care.   

Amber 2

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber with Shared Care

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber

Considered suitable for primary care prescribing following specialist initiation/recommendation.  

Green

Considered appropriate for prescribing in both secondary and primary care. Suitable for initiation in primary care.   

netFormulary